Previous close | 39.20 |
Open | 38.20 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 38.20 - 38.20 |
52-week range | 38.20 - 39.20 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 21 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually. The abstract describ
The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional growth stocks. The post 1 incredible growth stock I can’t find on the FTSE 100 appeared first on The Motley Fool UK.
It might be of some concern to shareholders to see the CRISPR Therapeutics AG ( NASDAQ:CRSP ) share price down 17% in...